Post Marketing Information DHCPL 30/11/2017 Important findings from a supplementary exploratory study on Dengvaxia® to assess long term safety and efficacy of Dengvaxia® from Phase IIb/III studies PEM 13/12/2022 Physician Educational Material Dengvaxia™ PMG 27/04/2023 Patient Medication Guide Dengvaxia™
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Dengvaxia Injection, Powder, For Suspension, CYD Dengue Virus Serotype 1 4.5 - 6 log10 CCID50/dose + CYD Dengue Virus Serotype 2 4.5 - 6 log10 CCID50/dose + CYD Dengue Virus Serotype 3 4.5 - 6 log10 CCID50/dose + CYD Dengue Virus Serotype 4 4.5 - 6 log10 CCID50/dose Changi General Hospital KK Women's and Children's Hospital
SUBCUTANEOUS Select a brand starting with the letter: D DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION [SIN15096P]